Tecentriq 840 Mg. Tecentriq 1 200 Mg. 840 mg. 1 200 mg Concentrate for solution for infusion
PDF Leaflet Revision Date: 13 February 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of various cancers including metastatic urothelial carcinoma and non-small cell lung cancer.
Dosage (summary)
840 mg every 2 weeks or 1,200 mg every 3 weeks; adjust based on indication.
Special Populations
- Renal impairment
- Hepatic impairment
- Geriatric patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy; avoid breastfeeding during treatment and for 5 months after.
Key Drug Interactions
- Avoid systemic corticosteroids before starting
- No significant drug-drug interactions expected
Contraindications
- Hypersensitivity to atezolizumab
- Use of live vaccines
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Rash
- Infusion-related reactions
Counselling Points
- Monitor for signs of immune-mediated reactions
- Advise on contraception during treatment
- Inform about potential infusion reactions
Serious warnings
- Immune-mediated pneumonitis
- Hepatitis
- Colitis
- Endocrinopathies
- Severe cutaneous adverse reactions
Important Disclaimer
The Tecentriq 840 Mg. Tecentriq 1 200 Mg. 840 mg. 1 200 mg Concentrate for solution for infusion professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
